Moderna faces new lawsuit over lucrative coronavirus vaccine - The Washington Post

The suit is the second patent fight over the development of the messenger RNA shot.

Moderna, a 10-year-old Cambridge-based biotechnology firm that had not marketed any product before the pandemic, has said it expects coronavirus vaccine sales to top $19 billion in 2022. Arbutus and … [+2790 chars]

full article...